DUBAI, UAE, Dec. 4, 2023 /PRNewswire/ — MiL.k team which is the project team of MiL.k DApp service, announced that its main currency, Milk Coin (MLK) is newly listed on Bybit at UTC 10:00 on 4th Dec 2023.

Bybit is one of the largest and popular crypto exchanges in global which has over 5 million user bases. By listed on Bybit, Milk Coin will be more easily and widely accepted in global crypto ecosystem with providing various benefits to global users. As the part of its new listing celebration, newly registered users who deposit or trade Milk Coin on Bybit will get rewards. Exciting collaboration with MiL.k and Bybit is ready to meet global users.

MiL.k is the blockchain based loyalty integration platform which has earned over 1.5 million user-base and strong partnership with major service companies such as airasia (global airline), OK Cashbag (Loyalty integration platform serviced by SK Group, the second largest group in Korea), L.Point (Loyalty coalition program of Lotte Group, the global group), etc. Through MiL.k, users can integrate reward points from different service companies into the single asset, Milk Coin (MLK) and exchange rewards points and Milk Coin with discounts. Milk Coin is tradable on global exchanges such as KuCoin, Gate.io, Huobi Global, Indodax and also, Korean exchanges which are the top 3 exchanges including Upbit, Bithumb and Coinone.

With the vision of building global integration loyalty platform, MiL.k is keep working hard on building strong alliance with Asia’s representative services and growing its utilization as marketing platform to provide useful features or beneficial services on MiL.k app. Based on global infrastructure that MiL.k has obtained, MiL.k is getting ready for a powerful leap forward.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Celltrion outlines a blueprint for innovative drug development built on its antibody…

ASTRI and Ecosystem Partners Present Advanced 5G Technologies at MWC Barcelona 2024

HONG KONG, Feb. 27, 2024 /PRNewswire/ — The Hong Kong Applied Science…

Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)

European approval is based on results from the Phase 3 BREAKWATER trial,…